Lazertinib (Leclaza) 80mg | Yuhan Korea Originator | GLT

Generic Information: Leclaza (South Korea)

Leclaza is the original South Korean brand of lazertinib, developed by Yuhan Corporation from a candidate molecule acquired from Genosco and later licensed to Johnson & Johnson for worldwide development. Hailed at home as a landmark of Korean drug innovation — and recognised with a Best Pharmaceutical Product award at the first Prix Galien Asia — Leclaza supplies eighty 80 mg tablets per pack and remains the reference presentation of the molecule in its birth market.

What Is Lazertinib (Leclaza) Used For?

Leclaza was first approved in Korea for lung cancers that had progressed after earlier EGFR inhibitors because of the T790M resistance mutation, then extended to untreated advanced disease. Today its principal use is alongside amivantamab as a first-line option for EGFR exon 19 deletion or L858R mutated non-small cell lung cancer, a combination that has earned approvals across the United States, Europe, Japan and China in addition to Korea.

How Does Lazertinib Work?

The molecule is engineered to shut off two disease-driving EGFR states — the original sensitising mutation and the T790M escape mutation — by forming a permanent chemical bond with the receptor's catalytic site. Normal EGFR function in skin and the digestive tract is largely left intact, which reduces the acne-like toxicity typical of first-generation drugs. Activity inside the central nervous system adds a defensive line against metastases that seed the brain.

Indications

Clinically, Leclaza serves EGFR-mutated NSCLC patients in two settings: after progression on an earlier EGFR inhibitor where T790M is present, and — more commonly now — as the oral component of first-line doublet therapy with amivantamab. Candidates undergo molecular profiling before treatment, and managing physicians weigh history of interstitial lung disease, cardiac conduction and clotting risk when planning the regimen.

Dosage

Standard dosing is 240 mg once daily by mouth irrespective of meals; tablets are swallowed intact and never divided. Twenty-four-hour coverage means the Korean 84-tablet pack conveniently matches a four-week cycle at three 80 mg tablets per day, aligning with amivantamab infusion visits. A forgotten dose is taken when noticed unless the next tablet is due within twelve hours, in which case it is skipped entirely.

Side Effects

Observed effects cluster around the skin and digestive tract: acneiform rash, nail inflammation, itching, stomatitis, diarrhoea and appetite loss, plus tiredness and aching muscles or joints. Blood tests commonly reveal reduced thyroid hormone or magnesium. Regimens that add amivantamab inherit that antibody's own risks — infusion reactions, venous thromboembolism and interstitial lung changes — so patients receive structured education on warning symptoms before the first cycle.

Storage

Leclaza tablets require only ordinary room-temperature storage in their sealed original packaging, away from humidity — refrigeration is unnecessary. Ambient-condition courier transport from GLT's Hong Kong-licensed facility preserves product quality end to end, with batch documentation enclosed in every shipment.

Why Choose Leclaza Through GLT?

Buying the Korean originator presentation connects patients and institutions to the very batch lineage that pioneered this molecule — Yuhan-manufactured Leclaza with Korean regulatory provenance, dispatched by GLT with traceable sourcing papers. For procurement teams benchmarking multiple presentations of lazertinib, GLT lists the US, China and Korea originator packs and the Laos generic side by side for transparent comparison.

How to Order

To order Leclaza (lazertinib) from GLT, reach us on WhatsApp at +86 15234153837 or by email at [email protected] — we confirm pack availability, delivery cost and timing to your country, and ship from a Hong Kong-licensed facility.

FAQ

Who makes Leclaza? Yuhan Corporation of South Korea developed and manufactures Leclaza; Johnson & Johnson's Janssen holds ex-Korea commercialisation rights under the Lazcluze name.

Why is the Korean pack 84 tablets? At the standard daily dose of three 80 mg tablets, an 84-tablet pack covers exactly 28 days of therapy.

Is Leclaza an original or a copy? It is the originator — the first lazertinib product ever approved (Korea, 2021), developed by Yuhan from the Genosco candidate molecule.